Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.

Slides:



Advertisements
Similar presentations
516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.
Advertisements

Oncologic Drugs Advisory Committee
Breast Cancer Systemic Therapy for Early Stage Disease
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
History of the randomized evidence on early breast cancer overall survival: Radiation vs no radiation after mastectomy L. Vakaet 2006.
SABCS 2011 Metastatic Breast Cancer Shiuh-Wen Luoh MD PhD Clinical Associate Professor Comprehensive Breast Cancer Clinic Hematology and Medical Oncology.
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
CONTROVERSIES IN ADJUVANT ENDOCRINE THERAPY AROMATASE INHIBITORS
Robertson JFR et al. J Clin Oncol 2009;27(27):
Systemic therapy for Metastatic Breast Cancer Jo Anne Zujewski, MD National Cancer Institute May 2011.
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
Study Of Letrozole Extension
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of.
The IBCSG August History of IBCSG In January 1976, Dr Jan Stjernswärd invited: Kurt Brunner, John Forbes, Percy Helman, Carl- Magnus Rudenstam,
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
These slides were released by the speaker for internal use by Novartis.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
These slides were released by the speaker for internal use by Novartis.
Intergroup trial CALGB 80101
Howard M. Sandler, MD University of Michigan Medical School
Outcome According to CYP2D6 Genotype Among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
IBCSG 22-00: Objective To evaluate the efficacy of a low- dose chemotherapy regimen, hypothesized to have anti- angiogenic activity, administered following.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
These slides were released by the speaker for internal use by Novartis
BIG 1-98/IBCSG Henning Mouridsen for the BIG 1-98 Collaborative Group Authors: Sunil Verma Date posted: December 22, 2008.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year.
Start or Switch?: Latest data from ABCSG/ARNO
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
“Big Data, Better Treatment”: The work of the Early Breast Cancer Trialists’ Collaborative Group Rory Collins BHF Professor of Medicine & Epidemiology.
Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting.
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal.
Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Lectures inEarly Breast Cancer A PowerPoint slide set based on images from: Lectures in Early Breast Cancer Part 3: Adjuvant Therapy in Early Breast Cancer.
Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.
Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial Patricia.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in pre-menopausal.
JOURNAL OF CLINICAL ONCOLOGY 25:
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
Bergh J et al. SABCS 2009;Abstract 23.
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Presentation transcript:

Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG

Tailored Treatment Investigations Premenopausal patients with endocrine- responsive disease (ER > 10% and/or PgR > 10%) Open questions related to adjuvant treatments: 1.Role of suppression of ovarian function 2.Role of AI 3.Role of chemotherapy in addition to endocrine therapies 4.Duration of GnRH analogue when combined with SERMS

SOFT: Suppression of Ovarian Function Trial (IBCSG 24-02; BIG 2-02) TEXT: Tamoxifen and Exemestane Trial (IBCSG 25-02; BIG 3-02) North American Intergroup and Breast International Group (BIG) participation Coordinating Group: International Breast Cancer Study Group (IBCSG) Pharmaceutical Partner: Pfizer STP Tailored Treatment Investigations Premenopausal patients with endocrine-responsive disease (ER > 10% and/or PgR > 10%)

SOFT Suppression of Ovarian Function Trial A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Gini Fleming and Prue Francis

SOFT: Background EBCTCG overview: Ovarian ablation effective adjuvant therapy in women < 50 EBCTCG overview: benefit of ovarian ablation uncertain in women < 50 if also receive chemotherapy

Does Overview underestimate ovarian ablation efficacy? Some were hormone receptor negative Most women < 50 who receive adjuvant chemotherapy become menopausal Need to test ovarian function suppression in group who can benefit i.e. remain premenopausal after chemo + receptor positive cancer

Amenorrhea after Chemotherapy 80% of women > 40 yrs after CMF x 6 < 50% women < 40 yrs after CMF Less amenorrhea with AC than CMF (34% vs 69%) Prognosis after CMF better in those who get amenorrhea

Combining Tamoxifen plus ovarian function suppression In advanced breast cancer there is a survival advantage to combined endocrine treatment (GnRH + Tam) vs. single hormonal treatment in premenopausal women

Women < 35 yrs with hormone receptor positive breast cancer Do poorly after adjuvant chemotherapy alone Worse prognosis than premenopausal women > 35 Paradoxically have worse prognosis than same age group with hormone receptor negative cancer when treated with adjuvant chemotherapy

SOFT [IBCSG 24-02, BIG 2-02] Patients who remain premenopausal within 6 months after CT, or receive tamoxifen alone as adequate treatment Premeno. ER  10% and/or PgR  10% Patients with estradiol (E 2 ) in the premenopausal range either after CT or without CT CT=chemotherapy; T=tamoxifen; E=exemestane; OFS=ovarian function suppression using triptorelin x 5 years or surgical oophorectomy or ovarian irradiation RANDOMIZERANDOMIZE T x 5y OFS + T x 5y OFS + E x 5y Any CT PremenopausalPremenopausal No CT Strata Target sample size: 3000 patients * *Randomization within a 8-month evaluation period after end of CT, or within 12 weeks after definitive surgery for patients with no CT

SOFT: Eligibility (the basics) Resected Breast Cancer ER and/or PgR positive (  10% IHC) Premenopausal

SOFT: Premenopausal Estradiol within institutional premenopausal range Measured between 2 wks and 8 mos post chemotherapy Transient amenorrhea which resolves is acceptable (with premenopausal E2 level) Amenorrhea on tamoxifen acceptable if estradiol level in premenopausal range

SOFT: Treatment CHEMOTHERAPY –Completed prior to randomization or not given ADJUVANT ENDOCRINE THERAPY –OFS by randomization (investigator choice of method: Triptorelin 3.75mg IM q 28 days x 5 y OR oophorectomy OR ovarian irradiation) –Tamoxifen/Exemestane by randomization RADIOTHERAPY –Optional after mastectomy –Required after breast-conservation

SOFT: Primary Objectives Compare OFS + T vs T Compare OFS + E vs T Compare OFS + E vs OFS + T Primary endpoint: Disease-free survival

SOFT: Statistical Considerations 3 pairwise comparisons, each tested at the 2-sided alpha level Target: 25% reduction in hazard 80% power Sample Size: 3000 patients

STP: Secondary Endpoints Overall survival Systemic disease-free survival Quality of life Sites of first treatment failure Late side effects of early menopause Incidence of second (non-breast) cancers Causes of death without cancer event

SOFT: OFS Triptorelin: 3.75 mg IM q28 days for 5 years from randomization unless: –relapse or intolerance Triptorelin supplied Zoladex allowed but not supplied Irreversible OFS allowed

Adjuvant Endocrine Therapy Exemestane 25 mg po daily for 5 years Tamoxifen 20 mg po daily for 5 years Exemestane/Tamoxifen should start after adjuvant chemotherapy has been completed or at least 6 weeks after the initiation of GnRH analogue, whichever is later NB if patient ceases GnRH, exemestane ineffective

Exemestane Irreversible inactivator of aromatase Steroidal structure

TEXT Tamoxifen and Exemestane Trial A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Olivia Pagani and Barbara Walley

TEXT [IBCSG 25-02, BIG 3-02] Patients who should receive OFS from the start Premeno. ER  10% and/or PgR  10% Candidates to begin GnRH analogue (triptorelin) from the start of adjuvant therapy Strata** Any CT No CT CT=chemotherapy; GnRH analogue=triptorelin x 5 yrs, but oophorectomy or radiation is allowed after 6 months RANDOMIZERANDOMIZE GnRH + Tamoxifen* x 5y +/- CT** GnRH + Exemestane* x 5yy +/- CT** *to begin at least 6 weeks after start of triptorelin or after CT, whichever is later. **choice of +/- CT may be made by previous randomization in the PERCHE trial. Target sample size: 1845 patients

TEXT + SOFT It is prospectively planned to combine data from the arms comparing exemestane plus ovarian function suppression (OFS) versus tamoxifen plus OFS in the SOFT trial with the data from the TEXT trial.

The Quality of Life (QL) component is an integral part of the current protocols Includes core QL indices (e.g., physical well-being, mood, coping) and focus on impact of menopausal symptoms (e.g., hot flushes, loss of sexual interest) Baseline assessment prior to randomization Every 6 months for first two years Annually in years 3 to 6 (total 9 times thru 6 yrs) See protocol section 10.0 and Appendix V STP: Quality of Life Study

QL Forms One-page QL Core Form (QLC) – [LASA scales] One-page QL Module Form (QLM) – [LASA scales] For English-speaking centers: Two-page QL Supplement Form (QLS) – [Likert scales] Missing QL Form (MQL) – for patients who do not participate or whenever an assessment is missed See protocol section 10.0 and Appendix V STP: Quality of Life Study

LASA scale example Likert scale example

STP Target and Actual Accrual (through July 31, 2007)

STP Information